0001683168-24-003550.txt : 20240516 0001683168-24-003550.hdr.sgml : 20240516 20240516105604 ACCESSION NUMBER: 0001683168-24-003550 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240516 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240516 DATE AS OF CHANGE: 20240516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 24953991 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 8-K 1 cns_8k.htm FORM 8-K
false 0001729427 0001729427 2024-05-16 2024-05-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 16, 2024

___________________________

 

CNS Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

___________________________

 

Nevada 001-39126 82-2318545

(State or other jurisdiction of

incorporation or organization)

 (Commission File Number) (I.R.S. Employer Identification No.)

 

2100 West Loop South, Suite 900

Houston, Texas 77027

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (800) 946-9185

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

___________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbols(s) Name of each exchange on which registered
Common stock, par value $0.001 per share CNSP The NASDAQ Stock Market LLC

 

   

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 16, 2024, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

  

Item 9.01.Financial Statements and Exhibits

 

(d) Exhibits

 

  Exhibit No. Exhibit Description
     
  99.1 Press release dated May 16, 2024
  104 Cover page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 2 

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CNS Pharmaceuticals, Inc.

  
       
       
  By: /s/ Chris Downs                          
    Chris Downs  
    Chief Financial Officer  
       
Dated: May 16, 2024      

 

 

 

 

 

 

 

 

 3 

 EX-99.1 2 cns_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

 

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025

 

Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure

 

HOUSTON, TX (May 16, 2024) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.

 

"With topline results in our ongoing, fully enrolled Berubicin trial for GBM expected in the first half of next year, we continue to plan for success. Our commitment to our dual mission to bring meaningful treatment options to GBM patients as well as value to all stakeholders remains unwavering," commented John Climaco, Chief Executive Officer of CNS Pharmaceuticals.

 

Clinical Development Progress

 

The trial design of the Company’s potentially pivotal trial of Berubicin included a pre-planned, non-binding interim futility analysis. The Company reached the criteria required by the study protocol to conduct this interim futility analysis, which an independent DSMB is responsible for conducting. The DSMB's charter mandated that they review the primary endpoint, Overall Survival, as well as secondary endpoints and safety data to determine whether the efficacy data for the risk-benefit profile warrants modification or discontinuation of the study. On December 18, 2023, the Company released the DSMB's recommendation which was to continue the study without modification. Management remains blinded to the data underlying the recommendation of the DSMB.

 

The Company expects to report topline data from its study of Berubicin in the first half of 2025, although it is impossible to accurately predict how long patients on the study may survive, which could impact the timing of the release of topline data.

 

The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with the agency for guidance on expediting the development and review process. Additionally, the Company has received Orphan Drug Designation from the FDA, which may provide seven years of marketing exclusivity upon approval of an NDA. For more information about the Berubicin clinical trial, visit clinicaltrials.gov and reference identifier NCT04762069.

 

 

 

 

 

 1 

 

 

Summary of Financial Results for the First Quarter 2024

 

The net loss for the three months ended March 31, 2024 was approximately $3.5 million compared to approximately $4.9 million for the comparable period in 2023. The change in net loss is attributable to a decrease in research organization ("CRO") expenses related to continued progress with the Company’s potentially pivotal clinical trial, as well as decreases in legal and professional fees and other expenses.

 

The Company reported research and development expenses of $2.4 million for the three months ended March 31, 2024 compared to approximately $3.6 million for the comparable period in 2023. The decrease in research and development expenses during the period were mainly attributed to the timing of CRO expenses related to continued progress with the Company’s potentially pivotal clinical trial.

 

General and administrative expense was approximately $1.1 million for the three months ended March 31, 2024 compared to approximately $1.4 million for the comparable period in 2023. The decrease in general and administrative expense was mainly attributable to decreases of approximately $118,000 in legal and professional expenses, $20,000 in insurance expenses and $58,000 in stock compensation, $39,000 in travel expenses and $29,000 in other general and administrative expenses, which were offset by increases of approximately $19,000 in marketing and advertising expenses.

 

As of March 31, 2024, the Company had cash of approximately $0.8 million.

 

About CNS Pharmaceuticals, Inc.

 

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

 

Forward-Looking Statements

 

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements include, without limitation, the timing of release of the top line data for the potentially pivotal trial of Berubicin for GBM. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

 

CONTACTS:

 

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

833-475-8247

CNSP@jtcir.com

 

 

 

 

 2 

 

 EX-101.SCH 3 cnsp-20240516.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cnsp-20240516_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cnsp-20240516_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 16, 2024
Entity File Number 001-39126
Entity Registrant Name CNS Pharmaceuticals, Inc.
Entity Central Index Key 0001729427
Entity Tax Identification Number 82-2318545
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 2100 West Loop South
Entity Address, Address Line Two Suite 900
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77027
City Area Code (800)
Local Phone Number 946-9185
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol CNSP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cnspharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cns_8k.htm cnsp-20240516.xsd cnsp-20240516_lab.xml cnsp-20240516_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cns_8k.htm": { "nsprefix": "CNSP", "nsuri": "http://cnspharma.com/20240516", "dts": { "inline": { "local": [ "cns_8k.htm" ] }, "schema": { "local": [ "cnsp-20240516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "cnsp-20240516_lab.xml" ] }, "presentationLink": { "local": [ "cnsp-20240516_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://cnspharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cns_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cns_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001683168-24-003550-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-003550-xbrl.zip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end XML 18 cns_8k_htm.xml IDEA: XBRL DOCUMENT 0001729427 2024-05-16 2024-05-16 iso4217:USD shares iso4217:USD shares false 0001729427 8-K 2024-05-16 CNS Pharmaceuticals, Inc. NV 001-39126 82-2318545 2100 West Loop South Suite 900 Houston TX 77027 (800) 946-9185 false false false false true false Common stock, par value $0.001 per share CNSP NASDAQ